Compare PEPG & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEPG | FOCL |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 193.0M |
| IPO Year | 2022 | 1998 |
| Metric | PEPG | FOCL |
|---|---|---|
| Price | $2.90 | $4.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $11.17 | N/A |
| AVG Volume (30 Days) | ★ 639.6K | 83.6K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $1.31 | $4.00 |
| 52 Week High | $7.80 | $6.40 |
| Indicator | PEPG | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 36.65 |
| Support Level | $1.60 | $4.01 |
| Resistance Level | $3.14 | $4.50 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 8.59 | 23.75 |
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.